1. Home
  2. RPGL vs IMMP Comparison

RPGL vs IMMP Comparison

Compare RPGL & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RPGL

Republic Power Group Limited Class A Ordinary Shares

N/A

Current Price

$2.41

Market Cap

74.0M

Sector

Technology

ML Signal

N/A

Logo Immutep Limited

IMMP

Immutep Limited

HOLD

Current Price

$0.38

Market Cap

76.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RPGL
IMMP
Founded
2015
1987
Country
Singapore
Australia
Employees
8
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
74.0M
76.6M
IPO Year
N/A
2012

Fundamental Metrics

Financial Performance
Metric
RPGL
IMMP
Price
$2.41
$0.38
Analyst Decision
Hold
Analyst Count
0
3
Target Price
N/A
$5.50
AVG Volume (30 Days)
4.5M
904.8K
Earning Date
05-16-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$445.09
Revenue Next Year
N/A
N/A
P/E Ratio
$21.40
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.21
$0.29
52 Week High
$13.06
$3.53

Technical Indicators

Market Signals
Indicator
RPGL
IMMP
Relative Strength Index (RSI) 47.53 34.00
Support Level $0.31 $0.29
Resistance Level $8.44 $0.39
Average True Range (ATR) 1.62 0.03
MACD 0.08 0.00
Stochastic Oscillator 16.97 6.97

Price Performance

Historical Comparison
RPGL
IMMP

About RPGL Republic Power Group Limited Class A Ordinary Shares

Republic Power Group Ltd is a provider of customized ERP software solutions, consulting and technical support services, and peripheral hardware to corporate clients and government agencies, including airports, cruise terminals, and technology, trading, and logistics companies. The Company operates from Singapore and has historically served clients in Singapore and Malaysia, offering ERP systems with functions such as accounting, procurement, workflow automation, real-time monitoring, and capabilities including planning, surveillance, and threat detection. The Company leverages artificial intelligence and modular algorithms to address complex operational requirements and integrates sensors, controls, and other hardware to enable IoT connectivity with autonomous or semiautonomous outcomes.

About IMMP Immutep Limited

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Share on Social Networks: